Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Apr 1;25(4):1155-1167.
doi: 10.31557/APJCP.2024.25.4.1155.

A Comprehensive Integration of Data Regarding the Correlation of TNF-α rs1800629 Polymorphism with Susceptibility to Cervical Cancer

Zahra Marzbanrad  1 , Mojgan Karimi-Zarchi  2 , Somayeyeh Noei-Teymoordash  1 , Maryam Motamedinasab  1   3 , Sepideh Azizi  4 , Shahla Noori-Ardebili  5 , Maedeh Barahman  6 , Maryam Yeganegi  7 , Ali Masoudi  8 , Kamran Alijanpour  9 , Maryam Aghasipour  10 , Kazem Aghili  11 , Hossein Neamatzadeh  12
Affiliations
Meta-Analysis

A Comprehensive Integration of Data Regarding the Correlation of TNF-α rs1800629 Polymorphism with Susceptibility to Cervical Cancer

Zahra Marzbanrad et al. Asian Pac J Cancer Prev. .

Abstract

Background: Cervical cancer, globally, ranks as the runner-up among the most prevalent forms of cancer affecting women. The role of the tumor necrosis factor alpha (TNF-α) polymorphism in the susceptibility to cervical cancer has been a subject of interest. However, the current evidence regarding this association remains inconclusive.

Methods: To address this uncertainty, eligible studies were systematically searched and retrieved from various databases including Cochrane Library, EMBASE, PubMed, Web of Science, CNKI, and Wanfang database. The search was conducted until September 01, 2023. The collected literature was then subjected to independent analysis by two authors. The pooled odds ratio along with the corresponding 95% confidence interval was calculated using different genetic models. Additionally, sensitivity and cumulative analyses were performed to assess the stability of the obtained results.

Results: A total of 29 case-control studies involving 8850 cases and 9286 controls were included in the present analysis. The findings revealed that the TNF-α rs1800629 polymorphism increased the risk of cervical cancer under the allele genetic model (A vs. G: OR = 1.277, 95% CI = 1.104-1.477, P = 0.001) in the general population. Subgroup analysis based on ethnicity demonstrated that this polymorphism was associated with an increased risk of cervical cancer in Caucasian and African women, but not in Asians. Furthermore, subgroup analysis based on country of origin indicated a significant correlation between the TNF-α rs1800629 polymorphism and an increased risk of cervical cancer in American and Chinese women, but not in Iranian women.

Conclusions: The findings from this meta-analysis suggest that the TNF-α rs1800629 polymorphism is a risk factor for cervical cancer in the general population, particularly in Caucasian and African women. However, further well-designed studies are warranted to validate these findings.

Keywords: Cervical cancer; Meta-analysis; Polymorphism; TNF-α.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Flow Diagram of Selecting Eligible Studies for the Meta-Analysis
Figure 2
Figure 2
Forest Plot of TNF-α rs1800629 Polymorphism with Cervical Cancer under the Allele Genetic Model (A vs. G)
Figure 3
Figure 3
Funnel Plot for Publication bias in the Meta-Analysis of TNF-α rs1800629 Polymorphism with Cervical Cancer. A: allele (A vs. G), B: homozygote (AA vs. GG), C: heterozygote (AG vs. GG)
Figure 3
Figure 3
Funnel Plot for Publication bias in the Meta-Analysis of TNF-α rs1800629 Polymorphism with Cervical Cancer. D: dominant (AA+AG vs. GG) and E: recessive (AA vs. AG+GG)
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Karimi Zarchi M, Behtash N, Chiti Z, Kargar S. Cervical cancer and hpv vaccines in developing countries. Asian Pac J Cancer Prev. 2009;10(6):969–74. - PubMed
    1. Sravani AB, Ghate V, Lewis S. Human papillomavirus infection, cervical cancer and the less explored role of trace elements. Biol Trace Elem Res. 2023;201(3):1026–50. - PMC - PubMed
    1. Hashemzehi A, Karimi-Zarchi M, Parsaeian SF. Association of il-6 -174g>c and -572g>c polymorphisms with susceptibility to cervical cancer and ovarian cancer. Asian Pac J Cancer Prev. 2021;22:2867–71. - PMC - PubMed
    1. Sharma K, Machalek DA, Toh ZQ, Amenu D, Muchengeti M, Ndlovu AK, et al. No woman left behind: Achieving cervical cancer elimination among women living with hiv. Lancet HIV. 2023;10(6):e412–e20. - PubMed
    1. Lee J, Ismail-Pratt I, Machalek DA, Kumarasamy S, Garland SM. The recovery strategies to support cervical cancer elimination in lower-and middle-income countries (lmics) following covid-19 disruptions. Prev Med Rep. 2023;35:102291. - PMC - PubMed

Publication types

Substances